Treatment outcomes in 63 cases of juvenile dermatomyositis-associated calcinosis
Authors' conclusion
Despite wide variations in treatment, many patients showed calcinosis improvement over time, especially those treated with IVIG.
Study context
- Population
- Patients with juvenile dermatomyositis (JDM) and calcinosis treated between 2003 and 2019 at 11 CARRA institutions
- Participants
- 63 patients11 institutions
- Exposure
- Association of treatment outcomes with patient, disease and treatment characteristics (e.g. Intravenous immunoglobulin (IVIG) vs treatments without IVIG)
- Outcome
- Calcinosis improvement
Methodological detailsmulti-institutional, multivariable Cox models, Kaplan-Meier estimates
- Multi-institutional
- Multivariable Cox models
- Kaplan-Meier estimates
Main finding
As reported in the abstract
Overall improved calcinosis
79%
n=50
Observational data: associations, not effects.
Further findings
Calcinosis improvement by anti-NXP2 or anti-MDA5 autoantibody
- Did not significantly affect probability of any calcinosis improvement
- P = 0.30
Patient and disease characteristics
- Median (IQR) age at JDM diagnosis, years
- 7.8 (4.1-11.1)
- Median (IQR) age at calcinosis diagnosis, years
- 9.4 (5.7-13.3)
- Calcinosis present at JDM diagnosis
- 32% (n=20)
- Active JDM at calcinosis diagnosis
- 76% (47/62)
- Anti-NXP2 (most common myositis autoantibody)
- 38%, 12/32
- Unique treatment regimens
- 103
Original publication
Treatment outcomes in 63 cases of juvenile dermatomyositis-associated calcinosis. Clin Exp Rheumatol. Published 31 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →